Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity against metastatic colorectal cancer, particularly in combination with chemotherapy. METHODS: Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kilogram of body weight every two weeks) and 411 to receive IFL plus placebo. The primary end point was overall survival. Secondary end points were progression-free survival, the response rate, the duration of the response, safety, and the quality of life. RESULTS: The median duration of survival was 20.3 months in the group given IFL plus bevacizumab, as compared with 15.6 months in the group given IFL plus placebo, corresponding to a hazard ratio for death of 0.66 (P<0.001). The median duration of progression-free survival was 10.6 months in the group given IFL plus bevacizumab, as compared with 6.2 months in the group given IFL plus placebo (hazard ratio for disease progression, 0.54; P<0.001); the corresponding rates of response were 44.8 percent and 34.8 percent (P=0.004). The median duration of the response was 10.4 months in the group given IFL plus bevacizumab, as compared with 7.1 months in the group given IFL plus placebo (hazard ratio for progression, 0.62; P=0.001). Grade 3 hypertension was more common during treatment with IFL plus bevacizumab than with IFL plus placebo (11.0 percent vs. 2.3 percent) but was easily managed. CONCLUSIONS: The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Necrosis promotes the expression of VEGFa, as dying tumor cells release signals that stimulate the growth of new blood vessels33,53.”
From Self-supervised learning reveals clinically relevant histomorphological patterns for therapeutic strategies in colon cancer (2025) · cites this paper as [33]
In the citing paper
“Subsequently, as several phase III trials had demonstrated that FOLFOX and XELOX are comparable in the context of metastatic colorectal cancer33–35”
From Self-supervised learning reveals clinically relevant histomorphological patterns for therapeutic strategies in colon cancer (2025) · cites this paper as [33]
In the citing paper
“It has been reported that increased SFK expression occurs in approximately 80% of CRC specimens when compared to the normal adjacent colonic epithelium (Hurwitz et al., 2004).”
From Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (2011) · cites this paper as Hurwitz et al., 2004
In the citing paper
“The median overall survival in the IFL and bevacizumab arm was 20.3 months versus 15.6 months in the IFL alone arm.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [46]
In the citing paper
“The anti-VEGF antibody bevacizumab (BEV) is used in combination with chemotherapy (FOLFOX or FOLFIRI) for the treatment of mCRC with activating mutations in the RAS/RAF/MAPK pathway [121].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [121]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Self-citationKim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Self-citationIrinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Self-citationYang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716
Self-citation
Research works printed but not linked: 4
- Presta LG, 1997, Cancer Res, 57, 4593
- Nissen NN, 1998, Am J Pathol, 152, 1445
- Hurwitz H, 2002, Prog Proc Am Soc Clin Oncol, 21, 82
- Benson AB, 2003, Prog Proc Am Soc Clin Oncol, 22, 243
Cited by
Items 701–800 of 1,082
Bao, L., You, B., Shi, S., Shan, Y., Zhang, Q., Yue, H., Zhang, J., Zhang, W., Shi, Y., Liu, Y., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0183-6 · Cited by 206
Crane, C. H., Ellis, L. M., Abbruzzese, J. L., Amos, C., Xiong, H. Q., Ho, L., Evans, D. B., Tamm, E. P., Ng, C., Pisters, P. W. T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6780 · Cited by 206
The VEGF Pathway in Cancer and Disease: Responses, Resistance, and the Path Forward
Kieran, M. W., Kalluri, R., & Cho, Y.-J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006593 · Cited by 206
Andreou, A., Aloia, T. A., Brouquet, A., Dickson, P. V., Zimmitti, G., Maru, D. M., Kopetz, S., Loyer, E. M., Curley, S. A., Abdalla, E. K., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e318283a4d1 · Cited by 204
Dineen, S. P., Lynn, K. D., Holloway, S. E., Miller, A. F., Sullivan, J. P., Shames, D. S., Beck, A. W., Barnett, C. C., Fleming, J. B., & Brekken, R. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6705 · Cited by 203
Integrins: Molecular targets in cancer therapy
Tucker, G. C. (2006) · Current Oncology Reports · doi:10.1007/s11912-006-0043-3 · Cited by 203
Rudge, J. S., Holash, J., Hylton, D., Russell, M., Jiang, S., Leidich, R., Papadopoulos, N., Pyles, E. A., Torri, A., Wiegand, S. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708865104 · Cited by 203
Monoclonal Antibodies in Cancer Therapy: 25 Years of Progress
Oldham, R. K., & Dillman, R. O. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7438 · Cited by 204
Outcomes after Resection of Synchronous or Metachronous Hepatic and Pulmonary Colorectal Metastases
Miller, G., Biernacki, P., Kemeny, N. E., Gonen, M., Downey, R., Jarnagin, W. R., D’Angelica, M., Fong, Y., Blumgart, L. H., & DeMatteo, R. P. (2007) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2007.04.039 · Cited by 203
Heinemann, V., Stintzing, S., Kirchner, T., Boeck, S., & Jung, A. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.11.005 · Cited by 203
Role of the NF-κB signaling pathway in the pathogenesis of colorectal cancer
Soleimani, A., Rahmani, F., Ferns, G. A., Ryzhikov, M., Avan, A., & Hassanian, S. M. (2020) · Gene · doi:10.1016/j.gene.2019.144132 · Cited by 203
Mody, R., Yu, A. L., Naranjo, A., Zhang, F. F., London, W. B., Shulkin, B. L., Parisi, M. T., Servaes, S.-E.-N., Diccianni, M. B., Hank, J. A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00203 · Cited by 202
Soliman, W., Lund‐Andersen, H., & Larsen, M. (2006) · Acta Ophthalmologica Scandinavica · doi:10.1111/j.1600-0420.2006.00736.x · Cited by 202
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer
Hecht, J. R., Patnaik, A., Berlin, J., Venook, A., Malik, I., Tchekmedyian, S., Navale, L., Amado, R. G., & Meropol, N. J. (2007) · Cancer · doi:10.1002/cncr.22915 · Cited by 202
Self-citationKienast, Y., Klein, C., Scheuer, W., Raemsch, R., Lorenzon, E., Bernicke, D., Herting, F., Yu, S., The, H. H., Martarello, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0081 · Cited by 201
Vié, N., Copois, V., Bascoul-Mollevi, C., Denis, V., Bec, N., Robert, B., Fraslon, C., Conseiller, E., Molina, F., Larroque, C., et al. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-14 · Cited by 200
Multiple Roles for the Receptor Tyrosine Kinase Axl in Tumor Formation
Holland, S. J., Powell, M. J., Franci, C., Chan, E. W., Friera, A. M., Atchison, R. E., McLaughlin, J., Swift, S. E., Pali, E. S., Yam, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0993 · Cited by 201
Maharaj, A. S. R., & D'Amore, P. A. (2007) · Microvascular Research · doi:10.1016/j.mvr.2007.03.004 · Cited by 195
Gasparini, G., Longo, R., Fanelli, M., & Teicher, B. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.022 · Cited by 200
Bertini, I., Cacciatore, S., Jensen, B. V., Schou, J. V., Johansen, J. S., Kruhøffer, M., Luchinat, C., Nielsen, D. L., & Turano, P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1543 · Cited by 202
Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action
Tilsed, C. M., Fisher, S. A., Nowak, A. K., Lake, R. A., & Lesterhuis, W. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.960317 · Cited by 197
“non-small cell lung cancer (9), colorectal cancer (10) breast cancer (11), mesothelioma (12) and pancreatic cancer (13)]; a complete response followed by progression [e.”
BackgroundAdam, R., de Haas, R. J., Wicherts, D. A., Aloia, T. A., Delvart, V., Azoulay, D., Bismuth, H., & Castaing, D. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7297 · Cited by 199
Norden-Zfoni, A., Desai, J., Manola, J., Beaudry, P., Force, J., Maki, R., Folkman, J., Bello, C., Baum, C., DePrimo, S. E., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0919 · Cited by 200
Levine, E. A., Stewart, J. H., Russell, G. B., Geisinger, K. R., Loggie, B. L., & Shen, P. (2007) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2006.12.048 · Cited by 199
Tumor Cell Plasticity in Ewing Sarcoma, an Alternative Circulatory System Stimulated by Hypoxia
van der Schaft, D. W. J., Hillen, F., Pauwels, P., Kirschmann, D. A., Castermans, K., oude Egbrink, M. G. A., Tran, M. G. B., Sciot, R., Hauben, E., Hogendoorn, P. C. W., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2468 · Cited by 199
Kieran, M. W., Turner, C. D., Rubin, J. B., Chi, S. N., Zimmerman, M. A., Chordas, C., Klement, G., Laforme, A., Gordon, A., Thomas, A., et al. (2005) · Journal of Pediatric Hematology/Oncology · doi:10.1097/01.mph.0000183863.10792.d4 · Cited by 199
Roles of VEGF-A signalling in development, regeneration, and tumours
Matsumoto, K., & Ema, M. (2014) · Journal of Biochemistry · doi:10.1093/jb/mvu031 · Cited by 198
Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy
Pisarsky, L., Bill, R., Fagiani, E., Dimeloe, S., Goosen, R. W., Hagmann, J., Hess, C., & Christofori, G. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.028 · Cited by 197
Advanced colorectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Van Cutsem, E., & Oliveira, J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp130 · Cited by 197
Sargent, D. J., Köhne, C. H., Sanoff, H. K., Bot, B. M., Seymour, M. T., de Gramont, A., Porschen, R., Saltz, L. B., Rougier, P., Tournigand, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.2879 · Cited by 196
“Although the biologic agents approved for use in colorectal cancer (bevacizumab, cetuximab, and panitumumab) are generally well tolerated, the addition of biologics to chemotherapy clearly increases the incidence of severe adverse events.(19,24,25) Thus, if a biologic is used in addition to chemotherapy for the treatm…”
BackgroundMiller, K. D., Trigo, J. M., Wheeler, C., Barge, A., Rowbottom, J., Sledge, G., & Baselga, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1923 · Cited by 198
Kim, K. B., Sosman, J. A., Fruehauf, J. P., Linette, G. P., Markovic, S. N., McDermott, D. F., Weber, J. S., Nguyen, H., Cheverton, P., Chen, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.6270 · Cited by 196
Rizzo, S., Genovesi-Ebert, F., Di Bartolo, E., Vento, A., Miniaci, S., & Williams, G. (2008) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-008-0774-y · Cited by 195
Wey, J. S., Fan, F., Gray, M. J., Bauer, T. W., McCarty, M. F., Somcio, R., Liu, W., Evans, D. B., Wu, Y., Hicklin, D. J., et al. (2005) · Cancer · doi:10.1002/cncr.21145 · Cited by 194
Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents
Zangari, M., Fink, L. M., Elice, F., Zhan, F., Adcock, D. M., & Tricot, G. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3875 · Cited by 194
Angiogenic factors as potential drug target: Efficacy and limitations of anti-angiogenic therapy
Gacche, R. N., & Meshram, R. J. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.05.002 · Cited by 193
Chinot, O. L., de La Motte Rouge, T., Moore, N., Zeaiter, A., Das, A., Phillips, H., Modrusan, Z., & Cloughesy, T. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0007-3 · Cited by 195
Lam, V. W. T., Laurence, J. M., Johnston, E., Hollands, M. J., Pleass, H. C. C., & Richardson, A. J. (2013) · HPB · doi:10.1111/j.1477-2574.2012.00607.x · Cited by 194
Immunomodulatory Activity of VEGF in Cancer
(2017) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2016.09.007 · Cited by 194
Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
Liu, G., Chen, T., Ding, Z., Wang, Y., Wei, Y., & Wei, X. (2021) · Cell Proliferation · doi:10.1111/cpr.13009 · Cited by 189
Hegde, P. S., Jubb, A. M., Chen, D., Li, N. F., Meng, Y. G., Bernaards, C., Elliott, R., Scherer, S. J., & Chen, D. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2535 · Cited by 193
“These aliquots were stored at 80 C until distribution to different sites on dry ice. Formalin-fixed paraffin-embedded archival tissue samples and matched baseline plasma samples were obtained from patients enrolled in the AVF2107 (12, 21) and AVF2938 (30) studies.”
MethodInfluentialGhafouri-Fard, S., Abak, A., Tondro Anamag, F., Shoorei, H., Fattahi, F., Javadinia, S. A., Basiri, A., & Taheri, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.658636 · Cited by 193
“5-FU has also been used in combination with novel cancer therapies especially targeted therapeutics including vascular endothelial growth factor (VEGF) inhibitors [bevacizumab (7), ziv-aflibercept (8), regorafenib (9) and ramucirumab (10)] and anti-epidermal growth factor receptor (EGFR) therapies [cetuximab (11) and…”
BackgroundCHEN, E., & PARK, C. H. (2006) · Retina · doi:10.1097/01.iae.0000225351.87205.69 · Cited by 193
Farnsworth, R. H., Lackmann, M., Achen, M. G., & Stacker, S. A. (2014) · Oncogene · doi:10.1038/onc.2013.304 · Cited by 193
Targeting the tumour vasculature: from vessel destruction to promotion
Guelfi, S., Hodivala-Dilke, K., & Bergers, G. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00736-0 · Cited by 183
Molecular Mechanisms of Preeclampsia
Hod, T., Cerdeira, A. S., & Karumanchi, S. A. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a023473 · Cited by 190
Li, P., Zhang, X., Wang, H., Wang, L., Liu, T., Du, L., Yang, Y., & Wang, C. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-1028 · Cited by 193
Prognostic Factors for Recurrence After Pulmonary Resection of Colorectal Cancer Metastases
Onaitis, M. W., Petersen, R. P., Haney, J. C., Saltz, L., Park, B., Flores, R., Rizk, N., Bains, M. S., Dycoco, J., D'Amico, T. A., et al. (2009) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2009.03.034 · Cited by 192
Vogelaar, I., van Ballegooijen, M., Schrag, D., Boer, R., Winawer, S. J., Habbema, J. D. F., & Zauber, A. G. (2006) · Cancer · doi:10.1002/cncr.22115 · Cited by 192
Minniti, G. C., Muni, R., Lanzetta, G., Marchetti, P., & Enrici, R. M. (2009) · PubMed · Cited by 228
Clinical and Biological Significance of Vascular Endothelial Growth Factor in Endometrial Cancer
Kamat, A. A., Merritt, W. M., Coffey, D., Lin, Y. G., Patel, P. R., Broaddus, R., Nugent, E., Han, L. Y., Landen, C. N., Spannuth, W. A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1017 · Cited by 192
Totzeck, M., Mincu, R. I., & Rassaf, T. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006278 · Cited by 192
Clinical Management of Oxaliplatin-Associated Neurotoxicity
Grothey, A. (2005) · Clinical Colorectal Cancer · doi:10.3816/ccc.2005.s.006 · Cited by 192
RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline
van Persijn van Meerten, E. L., Gelderblom, H., & Bloem, J. L. (2010) · European Radiology · doi:10.1007/s00330-009-1685-y · Cited by 191
Deenen, M. J., Tol, J., Burylo, A. M., Doodeman, V. D., de Boer, A., Vincent, A., Guchelaar, H.-J., Smits, P. H. M., Beijnen, J. H., Punt, C. J. A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2209 · Cited by 191
Hersey, P., Sosman, J., O'Day, S., Richards, J., Bedikian, A., Gonzalez, R., Sharfman, W., Weber, R., Logan, T., Buzoianu, M., et al. (2010) · Cancer · doi:10.1002/cncr.24821 · Cited by 189
Signaling Pathways Governing Tumor Angiogenesis
Sakurai, T., & Kudo, M. (2011) · Oncology · doi:10.1159/000333256 · Cited by 190
Hahn, N. M., Stadler, W. M., Zon, R. T., Waterhouse, D., Picus, J., Nattam, S., Johnson, C. S., Perkins, S. M., Waddell, M. J., & Sweeney, C. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6067 · Cited by 190
Steeghs, N., Gelderblom, H., Roodt, J. O. '., Christensen, O., Rajagopalan, P., Hovens, M., Putter, H., Rabelink, T. J., & de Koning, E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5050 · Cited by 190
Disorders of Vascular Permeability
Park-Windhol, C., & D'Amore, P. A. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044506 · Cited by 190
Intracameral Bevacizumab for Iris Rubeosis
Grisanti, S., Biester, S., Peters, S., Tatar, O., Ziemssen, F., & Bartz-Schmidt, K. U. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.02.045 · Cited by 192
Ethics of Phase 1 Oncology Studies: Reexamining the Arguments and Data
Agrawal, M., & Emanuel, E. J. (2003) · JAMA · doi:10.1001/jama.290.8.1075 · Cited by 190
Cohen, S. J., Alpaugh, R. K., Gross, S., O'Hara, S. M., Smirnov, D. A., Terstappen, L. W. M. M., Allard, W. J., Bilbee, M., Cheng, J. D., Hoffman, J. P., et al. (2006) · Clinical Colorectal Cancer · doi:10.3816/ccc.2006.n.029 · Cited by 189
Systemic Therapy for Ovarian Cancer: Current Status and New Treatments
Ozols, R. F. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.03.011 · Cited by 188
Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases
Benoist, S., Pautrat, K., Mitry, E., Rougier, P., Penna, C., & Nordlinger, B. (2005) · British Journal of Surgery · doi:10.1002/bjs.5060 · Cited by 189
Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme
Verhoeff, J. J., van Tellingen, O., Claes, A., Stalpers, L. J., van Linde, M. E., Richel, D. J., Leenders, W. P., & van Furth, W. R. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-444 · Cited by 189
Emerging trends in colorectal cancer: Dysregulated signaling pathways (Review)
Ahmad, R., Singh, J., Wunnava, A., Al‑Obeed, O., Abdulla, M., & Srivastava, S. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.4847 · Cited by 189
Rosenfeld, P. J., Heier, J. S., Hantsbarger, G., & Shams, N. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.01.027 · Cited by 189
VEGF inhibition: insights from preclinical and clinical studies
Crawford, Y., & Ferrara, N. (2009) · Cell and Tissue Research · doi:10.1007/s00441-008-0675-8 · Cited by 188
Self-citationRoland, C. L., Dineen, S. P., Lynn, K. D., Sullivan, L. A., Dellinger, M. T., Sadegh, L., Sullivan, J. P., Shames, D. S., & Brekken, R. A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0280 · Cited by 188
Covey, A. M., Brown, K. T., Jarnagin, W. R., Brody, L. A., Schwartz, L., Tuorto, S., Sofocleous, C. T., D'Angelica, M., Getrajdman, G. I., DeMatteo, R., et al. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e31815ed693 · Cited by 189
Masi, G., Vasile, E., Loupakis, F., Cupini, S., Fornaro, L., Baldi, G., Salvatore, L., Cremolini, C., Stasi, I., Brunetti, I., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq456 · Cited by 188
Rosen, L. S., Kurzrock, R., Mulay, M., Van Vugt, A., Purdom, M., Ng, C., Silverman, J., Koutsoukos, A., Sun, Y.-N., Bass, M. B., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.8170 · Cited by 188
Deacetylation of serine hydroxymethyl-transferase 2 by SIRT3 promotes colorectal carcinogenesis
Wei, Z., Song, J., Wang, G., Cui, X., Zheng, J., Tang, Y., Chen, X., Li, J., Cui, L., Liu, C.-Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06812-y · Cited by 185
Workman, P., Aboagye, E. O., Chung, Y.-L., Griffiths, J. R., Hart, R., Leach, M. O., Maxwell, R. J., McSheehy, P. M. J., Price, P. M., & Zweit, J. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj162 · Cited by 188
Tumor stroma as targets for cancer therapy
Zhang, J., & Liu, J. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.10.003 · Cited by 187
VEGF and TGF-β are required for the maintenance of the choroid plexus and ependyma
Maharaj, A. S. R., Walshe, T. E., Saint-Geniez, M., Venkatesha, S., Maldonado, A. E., Himes, N. C., Matharu, K. S., Karumanchi, S. A., & D'Amore, P. A. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072041 · Cited by 187
Welch, S., Spithoff, K., Rumble, R. B., & Maroun, J. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp533 · Cited by 187
Lam, V. W. T., Spiro, C., Laurence, J. M., Johnston, E., Hollands, M. J., Pleass, H. C. C., & Richardson, A. J. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-011-2061-0 · Cited by 186
Intricacies of Bevacizumab-Induced Toxicities and Their Management
Gressett, S. M., & Shah, S. R. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l426 · Cited by 187
Angiogenesis Inhibitor Therapies: Focus on Kidney Toxicity and Hypertension
Izzedine, H., Rixe, O., Billemont, B., Baumelou, A., & Deray, G. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.04.025 · Cited by 186
Tumor microenvironment and progression
Dvorak, H. F., Weaver, V. M., Tlsty, T. D., & Bergers, G. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.21709 · Cited by 186
Chen, H. X., Mooney, M., Boron, M., Vena, D., Mosby, K., Grochow, L., Jaffe, C., Rubinstein, L., Zwiebel, J., & Kaplan, R. S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1573 · Cited by 186
Lambrechts, D., Claes, B., Delmar, P., Reumers, J., Mazzone, M., Yesilyurt, B. T., Devlieger, R., Verslype, C., Tejpar, S., Wildiers, H., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70231-0 · Cited by 187
Shah, M. A., Jhawer, M., Ilson, D. H., Lefkowitz, R. A., Robinson, E., Capanu, M., & Kelsen, D. P. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.0770 · Cited by 186
Do Oncologists Believe New Cancer Drugs Offer Good Value?
Nadler, E., Eckert, B., & Neumann, P. J. (2006) · The Oncologist · doi:10.1634/theoncologist.11-2-90 · Cited by 187
The Role of Prostaglandins and Other Eicosanoids in the Gastrointestinal Tract
Wang, D., Mann, J. R., & Dubois, R. N. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.09.080 · Cited by 186
Ets1 and ets2 are required for endothelial cell survival during embryonic angiogenesis
Wei, G., Srinivasan, R., Cantemir-Stone, C. Z., Sharma, S. M., Santhanam, R., Weinstein, M., Muthusamy, N., Man, A. K., Oshima, R. G., Leone, G., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211391 · Cited by 185
Heinemann, V., Stintzing, S., Modest, D. P., Giessen-Jung, C., Michl, M., & Mansmann, U. R. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.06.116 · Cited by 185
Treatment of the elderly colorectal cancer patient: SIOG expert recommendations
Papamichael, D., Audisio, R., Horiot, J.-C., Glimelius, B., Sastre, J., Mitry, E., Van Cutsem, E., Gosney, M., Köhne, C.-H., & Aapro, M. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn532 · Cited by 185
Metabolic and hypoxic adaptation to anti‐angiogenic therapy: a target for induced essentiality
McIntyre, A., & Harris, A. L. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404271 · Cited by 185
Rougier, P., Riess, H., Manges, R., Karasek, P., Humblet, Y., Barone, C., Santoro, A., Assadourian, S., Hatteville, L., & Philip, P. A. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.04.002 · Cited by 184
Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis
Hapani, S., Sher, A., Chu, D., & Wu, S. (2010) · Oncology · doi:10.1159/000314980 · Cited by 185
Cianfrocca, M. E., Kimmel, K. A., Gallo, J., Cardoso, T., Brown, M. M., Hudes, G., Lewis, N., Weiner, L., Lam, G. N., Brown, S. C., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603171 · Cited by 184
Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?
Asghar, U., & Meyer, T. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.07.031 · Cited by 182
Hypoxia Inducible Factor-1–Independent Pathways in Tumor Angiogenesis
Mizukami, Y., Kohgo, Y., & Chung, D. C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0111 · Cited by 184
Horlings, H. M., van Laar, R. K., Kerst, J.-M., Helgason, H. H., Wesseling, J., van der Hoeven, J. J. M., Warmoes, M. O., Floore, A., Witteveen, A., Lahti-Domenici, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.6969 · Cited by 184
Drug-induced Hypertension: An Unappreciated Cause of Secondary Hypertension
Grossman, E., & Messerli, F. H. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.05.024 · Cited by 183
Boss, D. S., Glen, H., Beijnen, J. H., Keesen, M., Morrison, R., Tait, B., Copalu, W., Mazur, A., Wanders, J., O'Brien, J. P., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.154 · Cited by 183
Cytogenetic Abnormalities of Tumor-Associated Endothelial Cells in Human Malignant Tumors
Akino, T., Hida, K., Hida, Y., Tsuchiya, K., Freedman, D., Muraki, C., Ohga, N., Matsuda, K., Akiyama, K., Harabayashi, T., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090202 · Cited by 183
Metadata
- Authors
- Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., & Kabbinavar, F.
- Affiliations
- Duke University (US)
- Kaiser Permanente (US)
- Genentech (US)
- Sarah Cannon (US)
- Hematology and Oncology Associates of Northeastern Pennsylvania (US)
- Vanderbilt University (US)
- California Pacific Medical Center (US)
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-06-03
- Volume
- 350
- Issue
- 23
- Pages
- 2335-2342
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2157769714
- Cited by
- 10,968
- References
- 14
- Citations by year
- 2026: 127 · 2025: 162 · 2024: 242 · 2023: 276 · 2022: 264 · 2021: 270 · 2020: 289 · 2019: 293 · 2018: 323 · 2017: 422 · 2016: 462 · 2015: 523 · 2014: 608 · 2013: 671 · 2012: 711
- FWCI
- 339.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k23ca085582-06)
- National Cancer Institute (K23 CA085582-04)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- bevacizumab, metastatic colorectal cancer, irinotecan, 5-fluorouracil, leucovorin, anti-VEGF monoclonal antibody, combination chemotherapy, overall survival, progression-free survival, hypertension, first-line therapy
- MeSH terms
- Bevacizumab, Irinotecan, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Neoplasm Metastasis, Quality of Life, Colorectal Neoplasms, Survival Analysis, Disease-Free Survival, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.